Program
GV101
A development code.
Its studies are mostly in Friedreich Ataxia, led by Graviton Bioscience.
Furthest: phase 2, since May 13, 20253 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Graviton Bioscience | 31 open or running | phase 2since May 13, 2025 | Sep 26, 2021 | Jul 2027phase 2 · NCT07870590 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 26, 2021First study: phase 1 study in Phase 1First studyNCT05068947 · 16 enrolled · United States
- May 13, 2025Phase 2 study in Weight ManagementNCT06979505 · 131 enrolled · United States, Israel
- Oct 6, 2026Phase 2 study in Friedreich AtaxiaNCT07870590 · 48 planned · United States
Ahead
- Jul 2027Primary completion: phase 2 study in Friedreich AtaxiaNCT07870590
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07870590Friedreich Ataxia · United States | 2 | Not yet recruiting | Jul 2027 | 48 |
| NCT06979505Weight Management · United States, Israel | 2 | Completed | Jan 28, 2026 | 131 |
| NCT05068947Phase 1 · United States | 1 | Completed | Oct 22, 2021 | 16 |
How it is read
Names in the registry
- “GV101”, 3 entries
Codes read as this program: GV101.
Conditions, from the studies’ own filings
- Friedreich Ataxia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.